Efficacy and Safety of Remibrutinib in Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.
Faiza Fatima, Ahmed Raza, Arsham Javed et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed remibrutinib for antihistamine-refractory chronic spontaneous urticaria (CSU), including three randomized controlled trials with 997 participants. Compared with placebo, remibrutinib improved disease control: the odds of achieving UAS7 ≤ 6 were higher (odds ratio 4.38; P < 0.0001), and UAS7 scores fell more (mean difference -9.45; P < 0.00001). Complete response (UAS7 ≤ 0) was not statistically significant. Overall adverse events, serious events, and discontinuations were similar, although several mild infections and petechiae were more frequent with remibrutinib.
Key findings
- Remibrutinib increased the odds of achieving UAS7 ≤ 6 versus placebo (odds ratio 4.38; P < 0.0001).
- UAS7 scores decreased more with remibrutinib than placebo (mean difference -9.45; P < 0.00001).
- Complete response (UAS7 ≤ 0) was not statistically significant (odds ratio 2.14; P = 0.16).
- Mild infections, nasopharyngitis, petechiae, and upper respiratory tract infections were more frequent; overall and serious adverse events and discontinuations were similar.
Why it matters
For CSU that remains uncontrolled despite antihistamines, these pooled trial results indicate that remibrutinib can improve symptom control compared with placebo. The findings also distinguish improvement in disease control from complete response, which was not statistically significant, and highlight mild adverse events that may warrant attention. Longer-term evidence and direct comparisons with omalizumab remain needed.
What to keep in mind
The meta-analysis included only three randomized trials, and the authors call for larger, long-term studies and direct comparisons with omalizumab.